LB Pharma is leading research in the field working to provide life-changing advances to patients with schizophrenia based upon proven science and existing approaches to treating psychiatric illnesses.
Focused on Innovation
LB Pharma has changed the chemical structure of amisulpride, creating a novel asset that could improve its efficacy and/or safety. LB-102 could be the 1st benzamide approved in the US to treat schizophrenia
If approved by the FDA, LB-102 would be the first benzamide atypical approved for the US psychiatry market. We’re on track for strong growth.
Commitment to our patients
We are dedicated to bringing LB-102 to the US market to help treat patients suffering from schizophrenia that are not responding well to existing medication(s).View Publications
LB Pharma’s leading innovation
LB Pharma's lead asset and the foundation of the company's growth is LB-102, N-Methyl amisulpride. If approved by the FDA, LB-102 would be the first benzamide atypical approved to treat schizophrenia for the US market. We are also developing other US-market focused versions of life-saving drugs to treat CNS disorders that are available overseas but currently not approved by the FDA for marketing in the US.